Funding round-up: Dualyx, NewBiologix, Capitainer, DiogenX

France: DiogenX, a regenerative medicine biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, has completed a €27.5m (US$30m) Series A financing round led by Boehringer Ingelheim Venture Fund (BIVF). In this round, BIVF was joined by new investors Roche Venture Fund, Eli Lilly and Omnes, and historic investors JDRF T1D…